Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TxCell Plans First In Man Trial Of Regulatory T-Cells

Executive Summary

Stéphane Boissel, CEO of TxCell, discusses the company's plans to advance its lead next-generation regulatory T-cell candidate into human studies, after having switched to a new platform, in a video interview with Scrip.

You may also be interested in...



Sangamo Buys TxCell To Get In Early on CAR-Tregs In Immunology

Sangamo is to pay €72m to acquire France's TxCell, a specialist in chimeric antigen receptor-modified regulatory T-cells. It hopes ultimately to apply its zinc finger nuclease gene editing technology to develop next-generation allogeneic CAR-Treg therapies for immunological conditions.

AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments

Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.

Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies

Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.

Topics

UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel